Cambridge biotech Biogen has won patent ruling and its shares went up by 1.5%.
The dispute was over its top-selling multiple sclerosis treatment Tecfidera and was brought upwards by Texas hedge fund manager Kyle Bass, who has been working for years to invalidate key intellectual property rights of Biogen and other biotechnology companies.
If The U.S. Patent Trial and Appeal Board would have ruled against Biogen’s revenue from the oral MS drug Tecfidera, which generated nearly $4 billion in sales last year, would have certainly suffered.
Source: The Boston Globe
